173 related articles for article (PubMed ID: 23364242)
1. Effect of the BCL2 gene polymorphism on survival in advanced-stage non-small cell lung cancer patients who received chemotherapy.
Masago K; Togashi Y; Fujita S; Nagai H; Sakamori Y; Okuda C; Kim YH; Mishima M
Oncology; 2013; 84(4):214-8. PubMed ID: 23364242
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.
Tiseo M; Giovannetti E; Tibaldi C; Camerini A; Di Costanzo F; Barbieri F; Burgers JA; Vincent A; Peters GJ; Smit EF; Ardizzoni A
Lung Cancer; 2012 Oct; 78(1):92-9. PubMed ID: 22889494
[TBL] [Abstract][Full Text] [Related]
4. Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer.
Bi N; Yang M; Zhang L; Chen X; Ji W; Ou G; Lin D; Wang L
Clin Cancer Res; 2010 Apr; 16(8):2383-90. PubMed ID: 20332326
[TBL] [Abstract][Full Text] [Related]
5. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
Kalikaki A; Kanaki M; Vassalou H; Souglakos J; Voutsina A; Georgoulias V; Mavroudis D
Clin Lung Cancer; 2009 Mar; 10(2):118-23. PubMed ID: 19362955
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms of BCL2 and BAX Genes Associate with Outcomes in Advanced Non-small cell lung cancer Patients treated with platinum-based Chemotherapy.
Peng Y; Wang L; Qing Y; Li C; Ren T; Li Q; Li M; Zhang S; Shan J; Wang G; Yang Z; Wang D
Sci Rep; 2015 Dec; 5():17766. PubMed ID: 26656462
[TBL] [Abstract][Full Text] [Related]
7. Prognostic implications of genetic variants in advanced non-small cell lung cancer: a genome-wide association study.
Lee Y; Yoon KA; Joo J; Lee D; Bae K; Han JY; Lee JS
Carcinogenesis; 2013 Feb; 34(2):307-13. PubMed ID: 23144319
[TBL] [Abstract][Full Text] [Related]
8. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.
Giachino DF; Ghio P; Regazzoni S; Mandrile G; Novello S; Selvaggi G; Gregori D; DeMarchi M; Scagliotti GV
Clin Cancer Res; 2007 May; 13(10):2876-81. PubMed ID: 17504986
[TBL] [Abstract][Full Text] [Related]
9. Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine.
Viñolas N; Provencio M; Reguart N; Cardenal F; Alberola V; Sánchez-Torres JM; Barón FJ; Cobo M; Maestu I; Moreno I; Mesía C; Izquierdo A; Felip E; López-Brea M; Márquez A; Sánchez-Ronco M; Tarón M; Santarpia MC; Rosell R;
Lung Cancer; 2011 Feb; 71(2):191-8. PubMed ID: 20627363
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor receptor 2 gene polymorphisms as predictors for tumor recurrence and overall survival in non-small-cell lung cancer.
Uzunoglu FG; Kaufmann C; Wikman H; Güngör C; Bohn BA; Nentwich MF; Reeh M; Pantel K; Bockhorn M; Kutup A; Mann O; Izbicki JR; Vashist YK
Ann Surg Oncol; 2012 Jul; 19(7):2159-68. PubMed ID: 22395975
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer.
Park JY; Lee WK; Jung DK; Choi JE; Park TI; Lee EB; Cho S; Park JY; Cha SI; Kim CH; Kam S; Jung TH; Jheon S
Clin Cancer Res; 2009 Mar; 15(5):1794-800. PubMed ID: 19240174
[TBL] [Abstract][Full Text] [Related]
12. VEGF polymorphisms and survival in early-stage non-small-cell lung cancer.
Heist RS; Zhai R; Liu G; Zhou W; Lin X; Su L; Asomaning K; Lynch TJ; Wain JC; Christiani DC
J Clin Oncol; 2008 Feb; 26(6):856-62. PubMed ID: 18281657
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms of vitamin D receptor and survival in early-stage non-small cell lung cancer patients.
Zhou W; Heist RS; Liu G; Neuberg DS; Asomaning K; Su L; Wain JC; Lynch TJ; Giovannucci E; Christiani DC
Cancer Epidemiol Biomarkers Prev; 2006 Nov; 15(11):2239-45. PubMed ID: 17119052
[TBL] [Abstract][Full Text] [Related]
14. The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non-small cell lung cancer.
Yoon KA; Yoon H; Park S; Jang HJ; Zo JI; Lee HS; Lee JS
J Thorac Cardiovasc Surg; 2012 Oct; 144(4):794-807. PubMed ID: 22818121
[TBL] [Abstract][Full Text] [Related]
15. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.
Hou X; Li Y; Luo RZ; Fu JH; He JH; Zhang LJ; Yang HX
Eur J Surg Oncol; 2012 Jun; 38(6):523-30. PubMed ID: 22440742
[TBL] [Abstract][Full Text] [Related]
16. Thrombocytosis and immunohistochemical expression of connexin 43 at diagnosis predict survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.
Du G; Yang Y; Zhang Y; Sun T; Liu W; Wang Y; Li J; Zhang H
Cancer Chemother Pharmacol; 2013 Apr; 71(4):893-904. PubMed ID: 23355038
[TBL] [Abstract][Full Text] [Related]
17. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
Ryu JS; Hong YC; Han HS; Lee JE; Kim S; Park YM; Kim YC; Hwang TS
Lung Cancer; 2004 Jun; 44(3):311-6. PubMed ID: 15140544
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy.
Koch A; Fohlin H; Sörenson S
J Thorac Oncol; 2009 Mar; 4(3):326-32. PubMed ID: 19155996
[TBL] [Abstract][Full Text] [Related]
19. Personalized peptide vaccination in patients with refractory non-small cell lung cancer.
Yoshiyama K; Terazaki Y; Matsueda S; Shichijo S; Noguchi M; Yamada A; Mine T; Ioji T; Itoh K; Shirouzu K; Sasada T; Takamori S
Int J Oncol; 2012 May; 40(5):1492-500. PubMed ID: 22307435
[TBL] [Abstract][Full Text] [Related]
20. A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer.
Sung WW; Wang YC; Cheng YW; Lee MC; Yeh KT; Wang L; Wang J; Chen CY; Lee H
Clin Cancer Res; 2011 Sep; 17(18):5991-9. PubMed ID: 21807637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
